Single Source: National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) (U24 Clinical Trial Not Allowed)
ID: 359141Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $9M

Eligible Applicants

Public and State Controlled Institutions of Higher Education

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359141

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-002.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a non-competitive funding opportunity for a single source cooperative agreement to Indiana University Indianapolis for the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD). This initiative aims to enhance NCRAD's infrastructure, expand sample collections, and improve biomarker research to support the growing needs of the Alzheimer's research community. The NCRAD will provide critical biospecimen support and facilitate data sharing between clinical data and biosamples, fostering collaboration in the scientific community. The total funding amount is approximately $14.77 million over a maximum of five years, with a submission deadline of October 17, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-26-002-Full-Announcement.html
    RFA-AG-26-002.html
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is announcing a non-competitive funding opportunity for a single source cooperative agreement to Indiana University Indianapolis. This initiative supports the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), which serves as a vital biorepository for research on Alzheimer's and related diseases. The funding, set at approximately $14.77 million over a maximum of five years, aims to further enhance NCRAD's infrastructure, expand sample collections, and improve biomarker research while addressing the increasing needs of the Alzheimer's research community. The NCRAD will maintain and enhance its repository, providing critical biospecimen support, including various biological samples and lab expertise. It will also ensure robust data sharing and linkages between clinical data and biosamples to facilitate academic and industry research. The application process is restricted to Indiana University Indianapolis, and submissions must follow specific guidelines and timelines to be considered. This initiative underscores the federal commitment to advancing research on aging and neurodegenerative diseases, leveraging a central resource to foster collaboration in the scientific community.
    Similar Opportunities
    Forecast for The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the NINDS Human Biospecimen and Data Repository, aimed at advancing research in neurological disorders. This initiative will establish a repository to maintain and expand a collection of biospecimens, which will be made available to qualified academic and industry researchers to support basic, translational, and clinical research efforts. The total estimated funding for this program is $1,950,000, with one award anticipated, and interested applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on August 25, 2025. For further inquiries, potential applicants can contact Dr. Rebecca Price at rebecca.price@nih.gov or by phone at 301-827-3587.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Analytical and Clinical Validation of Biomarkers for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD)" (PAR-23-258), aimed at supporting the validation of biomarkers to enhance therapy development and clinical practices. This initiative seeks applications that focus on achieving rigorous analytical and clinical validation of biomarkers, aligning with the standards set by the FDA’s Biomarker Qualification Program. The program is crucial for advancing research strategies that validate candidate biomarkers across diverse populations, thereby facilitating their use in clinical trials and medical product development. Interested applicants, including various educational and community organizations, must submit their proposals by March 6, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine," aimed at supporting integrative, cross-disciplinary research projects focused on understanding the genomic factors involved in Alzheimer's Disease (AD) and Alzheimer's Disease Related Dementias (ADRD). The initiative seeks to leverage innovative techniques and advanced analytical methods, including machine learning and comparative genomic analysis, to explore the genomic drivers of neurodegeneration through sophisticated disease models and interdisciplinary approaches. This cooperative agreement does not require cost sharing and is open to a wide range of eligible applicants, including non-domestic entities and tribal governments, with applications expected to be solicited starting in August 2026. For further inquiries, interested parties may contact Dr. Alison Yao at 301-827-7264 or via email at yaoal@nia.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Deriving Common Data Elements from Real-World Data for Alzheimer�s Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at developing Common Data Elements (CDEs) for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) utilizing Real-World Data (RWD) from electronic health records and CMS claims. The objective is to enhance data harmonization and interoperability among disparate RWD systems, thereby facilitating more efficient research and faster production of real-world evidence. This funding opportunity, categorized as a cooperative agreement, has an estimated total program funding of $4 million, with a maximum award ceiling of $2.5 million, and is expected to result in one award. Interested applicants should prepare for the anticipated application due date in June 2024, following the expected publication of the NOFO in March 2024.
    Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a non-competitive funding opportunity for a cooperative agreement to support the Human Genetic Cell Repository (HGCR), with a focus on maintaining and distributing a diverse collection of human cell lines and DNA samples for biomedical research. The initiative aims to enhance the repository's capacity by acquiring new cell lines from diverse populations, ensuring ethical practices in sample collection, and promoting inclusivity in research efforts. This funding opportunity provides up to $1.75 million annually for a five-year project period, with applications due by June 10, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the funding announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-055.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.